Atwood & Palmer Inc United Therapeutics Corp Transaction History

Atwood & Palmer Inc

$1.43 Billion
Q4 2024

A detailed history of Atwood & Palmer Inc transactions in United Therapeutics Corp stock. As of the latest transaction made, Atwood & Palmer Inc holds 64,575 shares of UTHR stock, worth $23.3 Million. This represents 1.59% of its overall portfolio holdings.

Number of Shares

64,575

Previous 64,056 0.81%

Holding current value

$23.3 Million

Previous $23 Million 0.74%

% of portfolio

1.59%

Previous 1.58%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Jan 16, 2025	BUY	$348.66 - $410.0 $180,954 - $212,790	519 Added 0.81%	64,575 $22.8 Million
Q3 2024 Oct 07, 2024	BUY	$311.04 - $363.55 $91,445 - $106,883	294 Added 0.46%	64,056 $23 Million
Q2 2024 Jul 10, 2024	BUY	$228.26 - $319.04 $37,662 - $52,641	165 Added 0.26%	63,762 $20.3 Million
Q1 2024 Apr 10, 2024	BUY	$210.76 - $249.51 $785,081 - $929,424	3,725 Added 6.22%	63,597 $14.6 Million
Q4 2023 Jan 12, 2024	BUY	$214.88 - $256.94 $65,108 - $77,852	303 Added 0.51%	59,872 $13.2 Million
Q3 2023 Oct 20, 2023	BUY	$211.82 - $248.24 $122,855 - $143,979	580 Added 0.98%	59,569 $13.5 Million
Q2 2023 Jul 18, 2023	BUY	$205.19 - $232.99 $88,231 - $100,185	430 Added 0.73%	58,989 $13 Million
Q1 2023 Apr 21, 2023	BUY	$212.99 - $276.17 $505,212 - $655,075	2,372 Added 4.22%	58,559 $13.1 Million
Q4 2022 Jan 31, 2023	BUY	$205.95 - $280.43 $148,284 - $201,909	720 Added 1.3%	56,187 $15.6 Million
Q3 2022 Oct 12, 2022	BUY	$203.3 - $244.17 $138,040 - $165,791	679 Added 1.24%	55,467 $11.6 Million
Q2 2022 Jul 21, 2022	BUY	$174.81 - $241.14 $9.58 Million - $13.2 Million	54,788 New	54,788 $12.9 Million

Others Institutions Holding UTHR

# of Institutions

723

Shares Held

60.9M

Call Options Held

123K

Put Options Held

104K

View Full List

About UNITED THERAPEUTICS Corp

Ticker UTHR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,516,300
Market Cap $16.4B
Description
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertensio...

More about UTHR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Atwood & Palmer Inc, based on Form 13F filings with the SEC.

News

Stay updated on Atwood & Palmer Inc with notifications on news.

Account

Atwood & Palmer Inc United Therapeutics Corp Transaction History